Fresh2 Group (Fresh2 Group) Tax Provision : $0.30 Mil (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group Tax Provision?

Fresh2 Group's tax provision for the three months ended in Jun. 2023 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2023 was $0.30 Mil.

Fresh2 Group Tax Provision Historical Data

The historical data trend for Fresh2 Group's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group Tax Provision Chart

Fresh2 Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Tax Provision

Get a 7-Day Free Trial

0.03

0.01

0.19

0.31

Fresh2 Group Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Tax Provision	Get a 7-Day Free Trial														0.01	-0.01	0.30	-	-

Fresh2 Group Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30 Mil.

Fresh2 Group (Fresh2 Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

0UC0:Germany

Address

650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108

Website

https://www.fresh2.co

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.